Skip to main content

Advertisement

SpringerLink
Log in

Use of Aminoglycosides in Elderly Patients

Pharmacokinetic and Clinical Considerations

  • Clinical Pharmacology
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

Aminoglycosides still represent a mainstay in the treatment of serious infections caused by Gram-negative bacilli in elderly patients. The aging process is accompanied by various physiological changes (e.g. alterations in body composition, impairments in certain organ functions), which may affect drug disposition and, subsequently, drug action. For aminoglycosides that are eliminated by the renal route, kidney function is the key parameter that should be taken into account when dosage regimens are calculated. Because there is a progressive decline in renal function with aging, the glomerular filtration rate should be estimated for each patient. Any change in creatinine clearance (CLCR) should result in a proportional correction of the dosage regimen. Such individualised dosage of aminoglycosides is particularly important because of their narrow therapeutic indices.

There are no conclusive data which indicate that age per se affects the elimination of aminoglycoside antibiotics. Overdosage may result from overestimation of renal function if crude serum creatinine (SCr) levels are used as a guide.

Nomograms for the relationship between SCr and CLCR have been developed. However, nomograms should be used with caution because substantial inter-individual variability in the plasma concentration-clearance relationship is still observed. Therefore, the choice of a maintenance dose based on an assessment of renal function, which may change rapidly, should always be considered as preliminary, and verification by serum concentration measurements is necessary.

As a result, the use of aminoglycoside serum concentration monitoring during therapy as the most important guide for dosage adjustment is particularly important in the elderly, and is indispensable in conjunction with frequent assessment of renal function. Although a matter of debate, the value of serum concentration monitoring has been demonstrated. With traditional multiple daily dosage, monitoring peak and trough concentrations has been recommended. For once daily dosage, however, no guidelines relating to therapeutic and/or toxic concentrations are available yet. In the meantime, we recommend monitoring at least trough concentrations.

Once daily administration of aminoglycosides has emerged as a new mode of treatment. Compared with multiple daily administration, once daily dosage may have a number of advantages, and many clinical trials comparing the efficacy or safety of both modes have shown either superiority or equivalence of the new mode in most indications. At present, however, no data from studies of once daily administration in young compared with elderly adults are available.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Knight JA. The process and theories of aging. Ann Clin Lab Sci 1995; 25: 1–12

    PubMed  CAS  Google Scholar 

  2. Shay JW. Aging and cancer: are telomeres and telomerase the connection?. Mol Med Today 1995; 1: 378–84

    PubMed  CAS  Google Scholar 

  3. Turner N, Scarpace PJ, Lowenthal DT. Geriatric pharmacology: basic and clinical considerations. Annu Rev Pharmacol 1992; 32: 271–302

    Google Scholar 

  4. Parker BM, Cusack BJ, Vestal RE. Pharmacokinetic optimisation of drug therapy in elderly patients. Drugs Aging 1995; 7: 10–8

    PubMed  Google Scholar 

  5. Schenker S. The aging liver. In: Abrams WB, Beers MH, Berkow R, editors. The Merck manual of geriatrics. 2nd ed. Whitehouse Station (NJ): Merck & Co. Inc., 1995: 696–9

    Google Scholar 

  6. Macias-Nuñez JF, Cameron JS. Renal function in the elderly. In: Cameron S, Davidson A, editors. Oxford textbook of clinical nephrology. Oxford: Oxford Medical Publishers, 1992: 56–70

    Google Scholar 

  7. Davies DF, Shock NW. Age changes in glomerular filtration rate, effect of renal plasma flow and tubular excretory capacity in adult males. J Clin Invest 1950; 29: 496–507

    PubMed  CAS  Google Scholar 

  8. Rowe JW, Andres R, Tobin JD, et al. The effect of age on cre-atinine clearance in man: a cross-sectional and longitudinal study. J Gerontol 1976; 31: 155–63

    PubMed  CAS  Google Scholar 

  9. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985; 33: 278–85

    PubMed  CAS  Google Scholar 

  10. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41

    PubMed  CAS  Google Scholar 

  11. Smythe M, Hoffman J, Kizy K, et al. Estimating creatinine clearance in elderly patients with low serum creatinine concentrations. Am J Hosp Pharm 1994; 51: 198–204

    PubMed  CAS  Google Scholar 

  12. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. 3rd ed. Baltimore (MD): Lea & Febiger, 1995

    Google Scholar 

  13. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial susceptibility testing: fourth international supplement. NCCLS document M100-S4. Villanova (PA): NCCLS, 1992

    Google Scholar 

  14. Lerner SA, Gaynes RP, Nordström L. Aminoglycosides. In: Gorbach SL, Barlett JG, Blacklow NR, editors. Infectious diseases. Philadelphia: WB. Saunders Company, 1992: 188–211

    Google Scholar 

  15. Moellering Jr RC. Clinical microbiology and the in vitro activity of aminoglycosides. In: Whelton A, Neu HC, editors. The aminoglycosides: microbiology, clinical use and toxicology. New York: Marcel Dekker, 1982: 65–95

    Google Scholar 

  16. Moellering Jr RC. In vitro antibacterial activity of the amino-glycoside antibiotics. Rev Infect Dis 1983; 5 Suppl.: S212–32

    Google Scholar 

  17. Betts RF, Valenti WM, Chapman SW, et al. Five-year surveillance of aminoglycoside usage in a university hospital. Ann Intern Med 1984; 100: 219–22

    PubMed  CAS  Google Scholar 

  18. Kucers A, Bennett NMcK. Kanamycin, gentamicin, tobramicin, amikacin, sisomicin, and netilmicin. In: Kucers A, Bennett NMcK, editors. The use of antibiotics: a comprehensive review with clinical emphasis. 4th ed. London: William Heine-mann Medical Books, 1987: 601–750

    Google Scholar 

  19. Cunha BA. Aminoglycosides: current role in antimicrobial therapy. Pharmacotherapy 1988; 8: 334–50

    PubMed  CAS  Google Scholar 

  20. Atkinson BA. Species incidence and trends of susceptibility to antibiotics in the United States and other countries: MIC and MBC. In: Lorian V, editor. Antibiotics in laboratory medicine. 2nd ed. Baltimore (MD): Williams & Wilkins, 1986: 995–1150

    Google Scholar 

  21. Young LS, Hewitt WL. Activity of five aminoglycoside antibiotics in vitro against Gram-negative bacilli and Staphy-lococcus aureus. Antimicrob Agents Chemother 1973; 4: 617–25

    PubMed  CAS  Google Scholar 

  22. Lortholary O, Tod M, Cohen Y, et al. Aminoglycosides. Med Clin North Am 1995; 79: 761–91

    PubMed  CAS  Google Scholar 

  23. Taber HW, Muller JP, Miller PF, et al. Bacterial uptake of aminoglycoside antibiotics. Microbiol Rev 1987; 51: 439–57

    PubMed  CAS  Google Scholar 

  24. Hannock REW, Bellido F. Antibiotic uptake: unusual results for unusual molecules. J Antimicrob Chemother 1992; 29: 235–9

    Google Scholar 

  25. Jackson GE, Lolans VT, Daikos GL. The inductive role of ionic binding in the bactericidal and postexposure effects of amino- glycoside antibiotics with implications for dosing. J Infect Dis 1990; 162: 408–13

    PubMed  CAS  Google Scholar 

  26. Weisblum B, Davies J. Antibiotic inhibitors of the bacterial ribosome. Bacteriol Rev 1968; 32 Suppl.: 493–528

    PubMed  CAS  Google Scholar 

  27. Davies J, Gorini L, Davies BD. Misreading of RNA code words induced by aminoglycoside antibiotics. Mol Pharmacol 1965; 1: 93–106

    PubMed  CAS  Google Scholar 

  28. Byran LE, Kwan S. Roles of ribosomal binding, membrane potential, and electron transport in bacterial uptake of streptomycin and gentamicin. Antimicrob Agents Chemother 1983; 23: 835–45

    Google Scholar 

  29. Hummel H, Böck A. Ribosomal changes resulting in antibiotic resistance. In: Byran LE, editor. Microbial resistance to drugs: handbook of experimental pharmacology. Vol. 91. Berlin: Springer-Verlag, 1989: 235–62

    Google Scholar 

  30. Busse H-J, Wöstmann C, Bakker EP. The bactericidal action of streptomycin: membrane permeabilization caused by the insertion of mistranslated proteins into the cytoplasmic membrane of Escherichia coli and subsequent caging of the antibiotic inside the cells due to degradation of these proteins. J Gen Microbiol 1992; 138: 551–61

    PubMed  CAS  Google Scholar 

  31. Davies JE. Aminoglycoside-aminocyclitol antibiotics and their modifying enzymes. In: Lorian V, editor. Antibiotics in laboratory medicine. 2nd ed. Baltimore (MD): Williams & Wil-kins, 1986: 790–809

    Google Scholar 

  32. Kadurugamuwa JL, Lam JS, Beveridge TJ. Interaction of gentamicin with the A band and B band lipopolysaccharides of Pseudomonas aeruginosa and its possible lethal effect. Antimicrob Agents Chemother 1993; 37: 715–21

    PubMed  CAS  Google Scholar 

  33. Nicas TI, Handock REW. Outer membrane protein H1 of Pseudomonas aeruginosa: involvement in adaptive and mutational resistance to ethylenediamine tetraacetate, polymyxin B, and gentamicin. J Bacteriol 1980; 143: 872–8

    PubMed  CAS  Google Scholar 

  34. Bryan LE. Aminoglycosides resistance. In: Bryan LE, editor. Antimicrobial drug resistance. Orlando (FL): Academic Press, 1984: 241–77

    Google Scholar 

  35. Modolell J, Davies BD. Mechanism of inhibition of ribosomes by streptomycin. Nature 1969; 224: 345–8

    PubMed  CAS  Google Scholar 

  36. Ozaki M, Mizushima S, Nomura M. Identification and functional characterization of the protein controlled by the streptomycin-resistant locus in E. coli. Nature 1969; 222: 333–9

    PubMed  CAS  Google Scholar 

  37. Eliopoulos GM, Wennersten C, Zighelboim-Daum S, et al. High-level resistance to gentamicin in clinical isolates of Streptococcus (enterococcus) faecium. Antimicrob Agents Chemother 1988; 32: 1528–32

    PubMed  CAS  Google Scholar 

  38. Shaw KJ, Rather PN, Hare RS, et al. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev 1993; 57: 138–63

    PubMed  CAS  Google Scholar 

  39. Davies J. Inactivation of antibiotics and the dissemination of resistance genes. Science 1994; 264: 375–82

    PubMed  CAS  Google Scholar 

  40. Hustinx WNM, Hoepelman IM. Aminoglycoside dosage regimens: is once a day enough?. Clin Pharmacokinet 1993; 25: 427–32

    PubMed  CAS  Google Scholar 

  41. Gilbert DN. Aminoglycosides. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett’s principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995: 279–306

    Google Scholar 

  42. Crossley KB, Peterson PK. Infections in the elderly. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett’s principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995: 2737–42

    Google Scholar 

  43. Crossley KB, Peterson PK. Infections in the elderly. Clin Infect Dis 1996; 22: 209–15

    PubMed  CAS  Google Scholar 

  44. Norma DC, Toledo SD. Infections in elderly persons. Clin Geriatr Med 1992; 8: 713–9

    Google Scholar 

  45. Yoshikawa TT. Empiric antimicrobial therapy. In: Yoshikawa TT, Norman DC, editors. Antimicrobial therapy in the elderly patient. New York: Marcel Dekker Inc., 1994: 469–77

    Google Scholar 

  46. Yoshikawa TT, Norman DC. Treatment of infections in elderly patients. Med Clin North Am 1995; 79: 651–61

    PubMed  CAS  Google Scholar 

  47. Begg EJ, Barclay ML. Aminoglycosides: 50 years on. Br J Clin Pharmacol 1995; 39: 597–603

    PubMed  CAS  Google Scholar 

  48. Chambers HF, Sande MA. The aminoglycosides. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors. Goodman & Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 1103–21

    Google Scholar 

  49. Zaske DE. Aminoglycosides. In: Yoshikawa TT, Norman DC, editors. Antimicrobial therapy in the elderly patient. New York: Marcel Dekker Inc., 1994: 183–235

    Google Scholar 

  50. Smith CR, Lipsky JJ, Laskin OL, et al. Double blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 1980; 302: 1106–9

    PubMed  CAS  Google Scholar 

  51. Neu HC. Clinical use of aminoglycosides. In: Whelton A, Neu HC, editors. The aminoglycosides: microbiology, clinical use and toxicology. New York: Marcel Dekker, 1982: 65–95

    Google Scholar 

  52. Buring JE, Evans DA, Mayrent SL, et al. Randomized trials of aminoglycoside antibiotics: quantitative overview. Rev Infect Dis 1988; 10: 951–7

    PubMed  CAS  Google Scholar 

  53. Beitino JS, Booker LA, Franck PA, et al. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 1993; 167: 173–9

    Google Scholar 

  54. Nicolle LE. Urinary tract infection in the elderly. J Antimicrob Chemother 1994; 33 Suppl. A: 99–109

    PubMed  Google Scholar 

  55. Prat V, Horcickova M, Hatala M, et al. Single-dose treatment with netilmicin for different clinical forms of urinary tract infection. Infection 1984; 12: 99–101

    PubMed  CAS  Google Scholar 

  56. Caramalli S, Amprimo MC, Cavalli G, et al. Effect and phar-macokinetics of netilmicin given as bolus intramuscular administration: an open comparative trial versus amikacin and fosfomycin in elderly patients affected by urinary tract infections. Int J Clin Pharmacol Res 1991; 11: 55–65

    PubMed  CAS  Google Scholar 

  57. Gorbach SL. Antimicrobial prophylaxis for appendectomy and colorectal surgery. Rev Infect Dis 1991; 13 Suppl. 10: S815–20

    PubMed  Google Scholar 

  58. Briedis DJ, Robson HG. Comparative activity of netilmicin, gentamicin, amikacin, and tobramycin against Pseudomonas aeruginosa and enterobacteriaceae. Antimicrob Agents Chemother 1976; 10: 592–7

    PubMed  CAS  Google Scholar 

  59. Tseng JT, Bryan LE. Mechanisms and spectrum of streptomycin in a natural population of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1972; 2: 136–41

    PubMed  CAS  Google Scholar 

  60. Konishi H, Goto M, Nakamoto Y, et al. Tobramycin inactivation by carbenicillin, ticarcillin, and piperacillin. Antimicrob Agents Chemother 1983; 23: 653–7

    PubMed  CAS  Google Scholar 

  61. Pittinger CB, Adamson R. Antibiotic blockade of neuromuscu-lar function. Annu Rev Pharmacol 1972; 12: 169–84

    PubMed  CAS  Google Scholar 

  62. Holtzman JL. Gentamicin and neuromuscular blockade [letter]. Ann Intern Med 1976; 84: 55

    PubMed  CAS  Google Scholar 

  63. Snavely SR, Hodges GR. The neurotoxicity of antibacterial agents. Ann Intern Med 1984; 101: 92–104

    PubMed  CAS  Google Scholar 

  64. Sanders DB, Kim YI, Howard Jr JR, et al. Intercostal muscle biopsy studies in myasthenia gravis: clinical correlations and the direct effects of drugs in myasthenic serum. Ann N Y Acad Sci 1981; 377: 544–66

    PubMed  CAS  Google Scholar 

  65. Hokkanen E. The aggravating effect of some antibiotics on the neuromuscular blockade in myasthenia gravis. Acta Neurol Scand 1964; 40: 346–52

    PubMed  CAS  Google Scholar 

  66. Lietman PS, Smith CR. Aminoglycoside nephrotoxicity in humans. Rev Infect Dis 1983; 5 Suppl. 2: S284–92

    Google Scholar 

  67. Kahlmeter G, Dahlager JI. Aminoglycoside toxicity: a review of clinical studies published between 1975 and 1982. J Anti-microb Chemother 1984; 13 Suppl. A: 9–22

    Google Scholar 

  68. Appel GB. Aminoglycoside nephrotoxicity. Am J Med 1990; 88 Suppl. 3C: 16S–20S

    PubMed  CAS  Google Scholar 

  69. Aronoff GR, Pottratz ST, Brier ME, et al. Aminoglycoside accumulation kinetics in rat renal parenchyma. Antimicrob Agents Chemother 1983; 23: 74–8

    PubMed  CAS  Google Scholar 

  70. Hostetler KY, Hall LB. Inhibition of kidney lysosomal phos-pholipases A and C by aminoglycoside antibiotics: possible mechanism of aminoglycoside toxicity. Proc Natl Acad Sci U S A 1982; 79: 1663–7

    PubMed  CAS  Google Scholar 

  71. Carlier MB, Laurent G, Claes PJ, et al. Inhibition of lysosomal phospholipases by aminoglycoside antibiotics: in vitro comparative studies. Antimicrob Agents Chemother 1983; 23: 440–9

    PubMed  CAS  Google Scholar 

  72. Morin JP, Fresel J, Fillasre J-P, et al. Aminoglycoside actions on rat kidney lysosomes in vivo and in vitro. In: Fillasre J-P, editor. Nephrotoxicity. New York: Masson, 1978: 253–68

    Google Scholar 

  73. Ngaha EO, Ogunleye IO. Studies on gentamicin-induced labiliza-tion of rat kidney lysosomes in vitro. Biochem Pharmacol 1983; 32: 2659–64

    PubMed  CAS  Google Scholar 

  74. Laurent G, Toubeau G, Heuson-Stiennon JA, et al. Kidney tissue repair after nephrotoxic injury: biochemical and morphological characterization. CRC Crit Rev Toxicol 1988; 19: 146–83

    Google Scholar 

  75. Sens MA, Hazen-Martin DJ, Blackburn JG, et al. Growth characteristics of cultured human proximal tubule cells exposed to aminoglycoside antibiotics. Ann Clin Lab Sci 1989; 19: 266–79

    PubMed  CAS  Google Scholar 

  76. Luft FC. Clinical significance of renal changes engendered by aminoglycosides in man. J Antimicrob Chemother 1984; 13 Suppl. A: 23–30

    PubMed  CAS  Google Scholar 

  77. Moore RD, Smith CR, Lipsky JJ, et al. Risk factors for nephrotoxicity in patients with aminoglycosides. Ann Intern Med 1984; 100: 352–7

    PubMed  CAS  Google Scholar 

  78. Moore RD, Smith CR, Lietman PS. Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis 1984; 149: 23–30

    PubMed  CAS  Google Scholar 

  79. Zaske DE. Aminoglycosides. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics: principles of therapeutic drug monitoring. Spokane (WA): Applied Therapeutics, 1986: 331–81

    Google Scholar 

  80. Barclay ML, Begg EJ. Aminoglycoside toxicity and relation to dose regimen. Adverse Drug React Toxicol Rev 1994; 13: 207–34

    PubMed  CAS  Google Scholar 

  81. McMartin DN, Engel SC. Effect of aging on gentamicin nephrotoxicity and pharmacokinetics in rats. Res Commun Chem Pathol Pharmacol 1982; 38: 193–207

    PubMed  CAS  Google Scholar 

  82. Gibey R, Dupond J-L, Alber D, et al. Predictive value of urinary N-acetyl-beta-D-glucosaminidase (NAG), alanine-amino-peptidase (AAP), and beta-2-microglobulin (β2M) in evaluating nephrotoxicity of gentamicin. Clin Chim Acta 1981; 116: 25–34

    PubMed  CAS  Google Scholar 

  83. Schentag JJ, Sutfin TA, Plaut ME, et al. Early detection of aminoglycoside nephrotoxicity with urinary beta-2-microglobulin. J Med 1978; 9: 201–10

    PubMed  CAS  Google Scholar 

  84. Schentag JJ, Plaut ME. Patterns of urinary beta-2 microglobulin excretion by patients treated with aminoglycosides. Kidney Int 1980; 17: 654–61

    PubMed  CAS  Google Scholar 

  85. Schentag JJ. Specificity of renal tubular damage criteria for aminoglycoside nephrotoxicity in critically ill patients. J Clin Pharmacol 1983; 23: 473–83

    PubMed  CAS  Google Scholar 

  86. Schentag JJ, Gengo FM, Plaut ME, et al. Urinary casts as an indicator of renal tubular damage in patients receiving aminoglycosides. Antimicrob Agents Chemother 1979; 16: 468–74

    PubMed  CAS  Google Scholar 

  87. Anderson RJ, Linas SL, Berns AS, et al. Nonoliguric acute renal failure. N Engl J Med 1977; 296: 1134–8

    PubMed  CAS  Google Scholar 

  88. Luft FC, Bloch R, Sloan RS, et al. Comparative nephrotoxicity of aminoglycoside antibiotics in rats. J Infect Dis 1978; 138: 541–5

    PubMed  CAS  Google Scholar 

  89. Williams PD, Bennett DB, Gleason CR, et al. Correlation between renal membrane binding and nephrotoxicity of aminoglycosides. Antimicrob Agents Chemother 1987; 31: 570–4

    PubMed  CAS  Google Scholar 

  90. Kaloyanides GJ. Antibiotic-related nephrotoxicity. Nephrol Dial Transplant 1994; 9 Suppl. 4: 130–4

    PubMed  Google Scholar 

  91. Downs NJ, Neihart RE, Dolezal JM, et al. Mild nephrotoxicity associated with vancomycin use. Arch Intern Med 1989; 149: 1777–81

    PubMed  CAS  Google Scholar 

  92. Rybak MJ, Albrecht LM, Boike SC, et al. Nephrotoxicity of vancomycin alone and with an aminoglycoside. J Antimicrob Chemother 1990; 25: 679–87

    PubMed  CAS  Google Scholar 

  93. Goetz MB, Sayers J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J Antimicrob Chemother 1993; 32: 325–34

    PubMed  CAS  Google Scholar 

  94. Gatell JM, San Miguel JG, Zamora L, et al. Comparison of the nephrotoxicity and auditory toxicity of tobramycin and ami-kacin. Antimicrob Agents Chemother 1983; 23: 897–901

    PubMed  CAS  Google Scholar 

  95. Govaerts PJ, Claes J, Van De Heying PH, et al. Aminoglyco-side-induced ototoxicity. Toxicol Lett 1990; 52: 227–51

    PubMed  CAS  Google Scholar 

  96. Fausti SA, Henry JA, Schaffer HI, et al. High-frequency audio-metric monitoring for early detection of aminoglycoside ototoxicity. J Infect Dis 1992; 165: 1026–32

    PubMed  CAS  Google Scholar 

  97. Huy PTB, Meulemans A, Wassef M, et al. Gentamicin persistence in rat endolymph and perilymph after a two-day constant infusion. Antimicrob Agents Chemother 1983; 23: 344–6

    Google Scholar 

  98. Huizing EH, de Groot JCMJ. Human cochlear pathology in aminoglycoside ototoxicity: a review. Acta Otolaryngol (Stockh) 1987; 436 Suppl.: 117–25

    CAS  Google Scholar 

  99. Matz GJ. Aminoglycoside cochlear ototoxicity. Otolaryngol Clin North Am 1993; 5: 705–12

    Google Scholar 

  100. Stupp H, Kupper K, Lagler F, et al. Inner ear concentrations and ototoxicity of different antibiotics in local and systemic application. Audiology 1973; 12: 350–63

    PubMed  CAS  Google Scholar 

  101. Ohtsuki K, Ohtani I, Aikawa T, et al. The ototoxicity and the accumulation in the inner ear of the various aminoglycoside antibiotics. Ear Res Jpn 1982; 13: 85–7

    Google Scholar 

  102. Dulon D, Aran JM, Zajic G, et al. Comparative uptake of gentamicin, netilmicin, and amikacin in the guinea pig cochlea and vestibule. Antimicrob Agents Chemother 1986; 30: 96–100

    PubMed  CAS  Google Scholar 

  103. Tran B, Huy P, Bernard P, et al. Kinetics of gentamicin uptake and release in the rat: comparison of inner ear tissues and fluids with other organs. J Clin Invest 1986; 77: 1492–1500

    Google Scholar 

  104. Hu DN, Qui WQ, Wu BT, et al. Genetic aspects of antibiotic-induced deafness: mitochondrial inheritance. J Med Genet 1991; 28: 79–83

    PubMed  CAS  Google Scholar 

  105. Hutchin T, Haworth I, Higashi K, et al. A molecular basis for human hypersensitivity to aminoglycoside antibiotics. Nucleic Acids Res 1993; 21: 4174–9

    PubMed  CAS  Google Scholar 

  106. Fischel-Ghodsian N, Prezant TR, Bu X, et al. Mitochondrial ribosomal RNA gene mutation in a patient with sporadic aminoglycoside ototoxicity. Am J Otolaryngol 1993; 14: 399–403

    PubMed  CAS  Google Scholar 

  107. Black FO, Pesznecker RN. Vestibular ototoxicity: clinical considerations. Otolaryngol Clin North Am 1993; 5: 713–37

    Google Scholar 

  108. Lombarte A, Yan HY, Popper AN, et al. Damage and regeneration of hair cell ciliary bundles in a fish ear following treatment with gentamicin. Hear Res 1993; 64: 166–74

    PubMed  CAS  Google Scholar 

  109. Forge A, Li L, Corwin JT, et al. Ultrastructural evidence for hair cell regeneration in the mammalian inner ear. Science 1993; 259: 1616–9

    PubMed  CAS  Google Scholar 

  110. Anniko M, Bagger-Sjoback D, Wersall J, et al. Gentamicin binding to the isolated crista ampullaris of the guinea pig. Res Commun Chem Pathol Pharmacol 1982; 37: 333–42

    PubMed  CAS  Google Scholar 

  111. Gatell JM, Ferran F, Araujo V, et al. Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides. Antimicrob Agents Chem-other 1987; 31: 1383–7

    CAS  Google Scholar 

  112. Manian FA, Stone WJ, Alford R. Adverse antibiotic effects associated with renal insufficiency. Rev Infect Dis 1990; 12: 236–49

    PubMed  CAS  Google Scholar 

  113. Brummett RE, Fox KE. Studies of aminoglycoside ototoxicity in animal models. In: Whetton A, Neu HC, editors. The aminoglycosides: microbiology, clinical use and toxicology. New York: Marcel Dekker, 1982: 419–51

    Google Scholar 

  114. Smith CR, Lietman PS. Effect of furosemide on aminoglyco-side-induced nephrotoxicity and auditory toxicity in humans. Antimicrob Agents Chemother 1983; 23: 133–7

    PubMed  CAS  Google Scholar 

  115. Kunin CM, Chalmers TC, Leevy CM, et al. Absorption of orally administered neomycin and kanamycin. N Engl J Med 1960; 262: 380–5

    PubMed  CAS  Google Scholar 

  116. Cox CE. Gentamicin. Med Clin North Am 1970; 54: 1305–15

    PubMed  CAS  Google Scholar 

  117. Breen KJ, Bryant RE, Levinson JD, et al. Neomycin absorption in man. Ann Intern Med 1972; 76: 211–8

    PubMed  CAS  Google Scholar 

  118. Barza M, Lauermann M. Why monitor serum levels of gentamicin?. Clin Pharmacokinet 1978; 3: 202–15

    PubMed  CAS  Google Scholar 

  119. Lanao JM, Dominguez-Gil A, Tabernero JM, et al. Disposition kinetics of amikacin in patients with renal impairment after intramuscular administration. Int J Clin Pharmacol Ther Tox-icol 1982; 20: 271–5

    CAS  Google Scholar 

  120. Wilson TW, Mahon WA, Inaba T, et al. Elimination of tritiated gentamicin in normal human subjects and in patients with severely impaired renal function. Clin Pharmacol Ther 1973; 14: 815–22

    PubMed  CAS  Google Scholar 

  121. Beauchamp D, Gourde P, Bergeron MG. Subcellular distribution of gentamicin in proximal tubular cells, determined by immunogold labeling. Antimicrob Agents Chemother 1991; 35: 2173–9

    PubMed  CAS  Google Scholar 

  122. Schwartz SN, Pazin GJ, Lyon JA, et al. A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects. J Infect Dis 1978; 138: 499–505

    PubMed  CAS  Google Scholar 

  123. Fong IW, Fenton RS, Bird R. Comparative toxicity of gentamicin versus tobramycin: a randomized prospective study. J Antimicrob Chemother 1981; 7: 81–8

    PubMed  CAS  Google Scholar 

  124. Zaske DE, Cipolle RJ, Rotschafer JC, et al. Gentamicin pharmacokinetics in 1,640 patients: method for control of serum concentrations. Antimicrob Agents Chemother 1982; 21: 407–411

    PubMed  CAS  Google Scholar 

  125. Schentag JJ, Jusko WJ. Renal clearance and tissue accumulation of gentamicin. Clin Pharmacol Ther 1977; 22: 364–70

    PubMed  CAS  Google Scholar 

  126. Welling PG, Baumueller A, Lau CC, et al. Netilmicin pharmacokinetics after single intravenous doses to elderly male patients. Antimicrob Agents Chemother 1977; 12: 328–34

    PubMed  CAS  Google Scholar 

  127. Bauer LA, Blouin RA. Influence of age on tobramycin pharmacokinetics in patients with normal renal function. Antimicrob Agents Chemother 1981; 20: 587–9

    PubMed  CAS  Google Scholar 

  128. Bauer LA, Blouin RA. Gentamicin pharmacokinetics: effect of aging in patients with normal renal function. J Am Geriatr Soc 1982; 30: 309–11

    PubMed  CAS  Google Scholar 

  129. Bauer LA, Blouin RA. Influence of age on amikacin pharmacokinetics in patients without renal disease: comparison with gentamicin and tobramycin. Eur J Clin Pharmacol 1983; 24: 639–42

    PubMed  CAS  Google Scholar 

  130. Zaske DE, Irvine R, Strand LM, et al. Wide interpatient variations in gentamicin dosage requirements for geriatric patients. JAMA 1982; 248: 3112–26

    Google Scholar 

  131. Matzke GR, Jameson JJ, Halstenson CE. Gentamicin disposition in young and elderly patients with various degrees of renal function. J Clin Pharmacol 1987; 27: 216–20

    PubMed  CAS  Google Scholar 

  132. El-Sayed YM, Islam SI. Effect of age and renal function on gentamicin pharmacokinetic parameters. Int J Clin Pharmacol 1989; 27: 503–9

    CAS  Google Scholar 

  133. Lackner TE, Birge S. Accuracy of pharmacokinetic dose determination of gentamicin in geriatric patients. DICP Ann Phar-macother 1990; 24: 29–32

    CAS  Google Scholar 

  134. Vanhaeverbeek M, Siska G, Herchuelz A. Pharmacokinetics of once-daily amikacin in elderly patients. J Antimicrob Chemother 1993; 31: 185–7

    PubMed  CAS  Google Scholar 

  135. Koo JM, Miller DR, Peterson CD. Gentamicin pharmacokinetics in elderly patients with normal renal function. J Pharm Technol 1994; 10: 14–17

    Google Scholar 

  136. Wagner JG. Fundamentals of clinical pharmacokinetics. Hamilton (IL): Drug Intelligence Publications, 1975: 82–4

    Google Scholar 

  137. Sawchuk RJ, Zaske DE. Pharmacokinetics of dosing regimes which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm 1976; 4: 183–95

    PubMed  CAS  Google Scholar 

  138. Sawchuk RJ, Zaske DE, Cipolle RJ, et al. Kinetic models for gentamicin dosing with the use of individual patient parameters. Clin Pharmacol Ther 1977; 21: 360–9

    Google Scholar 

  139. Benet LZ, Øie S, Schwartz JB. Appendix II. Design and optimization of dosage regimens: pharmacokinetic data. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors. Goodman & Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 1707–92

    Google Scholar 

  140. Prins JM, Koopmans RP, Büller HR, et al. Easier monitoring of aminoglycoside therapy with once-daily dosing schedules. Eur J Clin Microbiol Infect Dis 1995; 14: 531–5

    PubMed  CAS  Google Scholar 

  141. Zhanel GG, Hoban DJ, Harding GKM. The postantibiotic effect: a review of in vitro and in vivo data. DICP Ann Phar-macother 1991; 25: 153–63

    CAS  Google Scholar 

  142. Zhanel GG, Craig WA. Pharmacokinetic contributions to post-antibiotic effect: focus on aminoglycosides. Clin Pharmacokinet 1994; 24: 377–92

    Google Scholar 

  143. Gerber AU. Postantibiotic effect: an update and an outlook on clinical relevance. Curr Opin Infect Dis 1993; 6: 751–7

    Google Scholar 

  144. MacKenzie FM, Gould IM. The post-antibiotic effect. J Antimicrob Chemother 1993; 32: 519–37

    PubMed  CAS  Google Scholar 

  145. Barza M, Ioannidis JPA, Cappelleri JC, et al. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996; 312: 338–45

    PubMed  CAS  Google Scholar 

  146. Kumana CR, Yuen KY. Parenteral aminoglycoside therapy: selection, administration and monitoring. Drugs 1994; 47: 902–13

    PubMed  CAS  Google Scholar 

  147. Blaser J, König C. Once-daily dosing of aminoglycosides. Eur J Clin Microbiol Infect Dis 1995; 14: 1029–38

    PubMed  CAS  Google Scholar 

  148. Gonzalez P, Aguado JM, Martin MA, et al. Once-daily aminoglycoside dosing [letter]. Lancet 1993; 341: 895

    PubMed  CAS  Google Scholar 

  149. Labovitz E, Levison ME, Kaye D. Single-dose daily gentamicin therapy in urinary tract infection. Antimicrob Agents Chemother 1974; 6: 465–70

    PubMed  CAS  Google Scholar 

  150. Nordström L, Ringberg H, Cronberg S, et al. Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity?. J Antimicrob Chemother 1990; 25: 159–73

    PubMed  Google Scholar 

  151. Prins JM, Büller HR, Kuijper EJ, et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993; 341: 335–9

    PubMed  CAS  Google Scholar 

  152. Raz R, Adawi M, Romano S. Intravenous administration of gentamicin once daily versus thrice daily in adults. Eur J Clin Microbiol Infect Dis 1995; 14: 88–91

    PubMed  CAS  Google Scholar 

  153. Blaser J, Simmen HP, Thurnheer U, et al. Nephrotoxicity, high frequency ototoxicity, efficacy and serum kinetics of once versus thrice daily dosing of netilmicin in patients with serious infections. J Antimicrob Chemother 1995; 36: 803–14

    PubMed  CAS  Google Scholar 

  154. De Vries PJ, Verkooyen RP, Leguit P, et al. Prospective randomized study of once-daily versus thrice-daily netilmicin regimens in patients with intraabdominal infections. Eur J Clin Microbiol Infect Dis 1990; 9: 161–8

    PubMed  Google Scholar 

  155. Fan ST, Lau WY, Teoh-Chan CH, et al. Once daily administration of netilmicin compared with thrice daily, both in combination with metronidazole, in gangrenous and perforated appendicitis. J Antimicrob Chemother 1988; 22: 69–74

    PubMed  CAS  Google Scholar 

  156. Hansen M, Achen F, Carstensen C, et al. Once versus thrice-daily dosing of netilmicin in febrile immunocompromised patients: a randomised controlled study of efficacy and safety. J Drug Devel 1988; 1 Suppl. 3: 119–24

    Google Scholar 

  157. Hollender LF, Bahnini J, De Manzini N, et al. A multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intraabdominal infections. J Antimicrob Chemother 1989; 23: 773–83

    PubMed  CAS  Google Scholar 

  158. Mauracher EH, Lau WY, Kartowisastro H, et al. Comparison of once-daily and thrice-daily netilmicin regimens in serious systemic infections: a multicenter study in six Asian countries. Clin Ther 1989; 11: 604–13

    PubMed  CAS  Google Scholar 

  159. Muijsken MA, Vreede RW, van Dijk WC, et al. A randomized clinical study of efficacy and safety of once daily dosing versus conventional dosing of netilmicin in patients with severe infections. J Drug Devel 1988; 1 Suppl. 3: 145–6

    Google Scholar 

  160. Rozdzinski E, Kern WV, Reichle A, et al. Once-daily versus thrice-daily dosing of netilmicin in combination with β-lactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother 1993; 31: 585–98

    PubMed  CAS  Google Scholar 

  161. Sturm AW. Netilmicin in the treatment of Gram-negative bac-teremia: single daily versus multiple daily dosage. J Infect Dis 1989; 159: 931–7

    PubMed  CAS  Google Scholar 

  162. Ter Braak EW, de Vries PJ, Bouter KP, et al. Once-daily dosing regimen for aminoglycoside plus β-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med 1990; 89: 58–66

    PubMed  Google Scholar 

  163. Van der Auwera P, Meunier F, Ibrahim S, et al. Pharmaco-dynamic parameters and toxicity of netilmicin (6 milligrams/ kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection. Antimicrob Agents Chemother 1991; 35: 640–7

    PubMed  Google Scholar 

  164. Colandra T, International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single doses of ami-kacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119: 584–93

    Google Scholar 

  165. Giamarellou H, Yiallouros K, Petrikkos G, et al. Comparative kinetics and efficacy of amikacin administered once or twice daily in the treatment of systemic Gram-negative infections. J Antimicrob Chemother 1991; 27 Suppl. C: 73–9

    PubMed  Google Scholar 

  166. Maller R, Ahme H, Holmen C, et al. Once- versus twice-daily amikacin regimen: efficacy and safety in systemic Gram-negative infections. J Antimicrob Chemother 1993; 31: 939–48

    PubMed  CAS  Google Scholar 

  167. Marik PE, Lipman J, Kobilski S, et al. A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. J Antimicrob Chemother 1991; 28: 753–64

    PubMed  CAS  Google Scholar 

  168. Vanhaeverbeek M, Siska G, Douchamps J, et al. Comparison of the efficacy and safety of amikacin once or twice-a-day in the treatment of severe Gram-negative infections in the elderly. Int J Clin Pharmacol 1993; 31: 153–6

    CAS  Google Scholar 

  169. Gibson J, Johnson L, Snowdon L, et al. Single daily ceftriaxone and tobramycin in the empirical management of febrile neutropenic patients: a randomised trial. Int J Hematol 1993; 58: 63–72

    PubMed  CAS  Google Scholar 

  170. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93–9

    PubMed  CAS  Google Scholar 

  171. Verpooten GA, Giuliano RA, Verbist L, et al. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 1989; 45: 22–7

    PubMed  CAS  Google Scholar 

  172. De Broe ME, Verbist L, Verpooten GA. Influence of dosing schedule on renal cortical accumulation of amikacin and tobramycin in man. J Antimicrob Chemother 1991; 27 Suppl. C: 41–7

    PubMed  Google Scholar 

  173. Gilbert DN. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 1991; 35: 399–405

    PubMed  CAS  Google Scholar 

  174. Barclay ML, Begg EJ, Hickling KG. What is the evidence for once-daily aminoglycoside therapy?. Clin Pharmacokinet 1994; 27: 32–48

    PubMed  CAS  Google Scholar 

  175. Bates RD, Nahata MC. Once daily administration of aminogly-cosides. Ann Pharmacother 1994; 28: 757–65

    PubMed  CAS  Google Scholar 

  176. Cunningham R, Humphreys H. Once-daily gentamicin: translating theory into practice. Eur J Clin Pharmacol 1996; 50: 151–4

    PubMed  CAS  Google Scholar 

  177. Marra F, Partovi N, Jewesson P. Aminoglycoside administration as a single daily dose: an improvement to current practice or a repeat of previous errors?. Drugs 1996; 52: 344–70

    PubMed  CAS  Google Scholar 

  178. Dew RB, Susla GM. Once-daily aminoglycoside treatment. Infect Dis Clin Pract 1996; 5: 12–24

    Google Scholar 

  179. Galloe AM, Graudal N, Christensen HR, et al. Aminoglyco-sides: single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol 1995; 48: 39–43

    PubMed  CAS  Google Scholar 

  180. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996; 124: 717–25

    PubMed  CAS  Google Scholar 

  181. Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 1995; 39: 605–9

    PubMed  CAS  Google Scholar 

  182. Spector R, Park GD, Johnson GF, et al. Therapeutic drug monitoring. Clin Pharmacol Ther 1988; 43: 345–53

    PubMed  CAS  Google Scholar 

  183. Guglielmo BJ, Brooks GF. Antimicrobial therapy: cost-benefit considerations. Drugs 1989; 38: 473–80

    PubMed  CAS  Google Scholar 

  184. Destache CJ. Use of therapeutic drug monitoring in pharmaco-economics. Ther Drug Monit 1993; 15: 608–10

    PubMed  CAS  Google Scholar 

  185. Pancoast SJ. Aminoglycoside antibiotics in clinical use. Med Clin North Am 1988; 72: 581–612

    PubMed  CAS  Google Scholar 

  186. Meyer RD. Risk factors and comparisons of nephrotoxicity of aminoglycosides. Am J Med 1986; 80 Suppl. 6B: 119–25

    PubMed  CAS  Google Scholar 

  187. Klotz U, Godel A. Once-daily dosing of gentamicin: experience with therapeutic monitoring and Bayesian pharmacokinetics. Ther Drug Monit 1994; 16: 534–5

    PubMed  CAS  Google Scholar 

  188. Janknegt R. Aminoglycoside monitoring in the once- or twice-daily era: the Dutch situation considered. Pharm World Sci 1993; 15: 151–5

    PubMed  CAS  Google Scholar 

  189. Sheiner LB, Beal S, Rosenberg B, et al. Forecasting individual pharmacokinetics. Clin Pharmacol Ther 1979; 26: 294–305

    PubMed  CAS  Google Scholar 

  190. Burton ME, Brater DC, Chen PS, et al. A Bayesian feedback method of aminoglycoside dosing. Clin Pharmacol Ther 1985; 35: 349–53

    Google Scholar 

  191. Mailer R, Emanuelsson B-M, Isaksson B, et al. Amikacin once daily: a new dosing regimen based on drug pharmacokinetics. Scand J Infect Dis 1990; 22: 575–9

    Google Scholar 

  192. Mailer R, Isaksson B, Nilsson L, et al. A study of amikacin given once versus twice daily in serious infections. J Anti-microb Chemother 1988; 22: 75–9

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Auerbachstraße 112, D-70376, Stuttgart, Germany

    Klaus Mörike, Matthias Schwab & Ulrich Klotz

Authors
  1. Klaus Mörike
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthias Schwab
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ulrich Klotz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mörike, K., Schwab, M. & Klotz, U. Use of Aminoglycosides in Elderly Patients. Drugs & Aging 10, 259–277 (1997). https://doi.org/10.2165/00002512-199710040-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199710040-00003

Keywords

Search

Navigation